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Switching mRNA translation off and on is central to regulated gene expression, but what mecha-
nisms moderate the extent of switch-off? Yao et al. describe how basal expression from inter-
feron-gamma-induced transcripts is maintained during mRNA-specific translational repression.
This antagonistic mechanism utilizes a truncated RNA-binding factor generated by a unique
alternative polyadenylation event.For cells to function properly, proteins
have to be produced at the right time
and place and in the correct amount,
necessitating mechanisms for tightly con-
trolling gene expression. In recent years,
the importance of translational control
and its participation in regulatory net-
works that act at multiple levels of gene
expression has emerged. Regulation can
be either global, affecting almost all
mRNAs, or specific to an mRNA subset.
In many cases, mRNA-specific regulation
is effected by RNA-binding proteins that
bind control elements that are most
commonly located within the 50 or 30
untranslated regions (UTRs). Most of
these RNA-binding proteins are transla-
tional repressors that act by blocking
recruitment of the translational ma-
chinery. Intriguingly, in this issue of Cell,
Yao et al. (2012) provide evidence for
a mechanism that ensures basal expres-
sion, referred to as a ‘‘translational
trickle,’’ of a subset of proteins by antag-
onizing their mRNA-specific repression
(Figure 1). Interestingly this mechanism
is mediated by a truncated dominant-
negative form of one of the RNA-binding
proteins required for repression, pro-
duced in a unique alternative polyadeny-
lation event that converts a Tyr codon
into a stop codon.
Injury or infection activates the innate
immune system, prompting monocytes
and macrophages to express proinflam-
matory proteins that must be tightly
regulated, and ultimately switched off,
to facilitate resolution of inflammation
(Murray and Wynn, 2011). For instance,
interferon-gamma (IFN-g) stimulationinduces several transcripts (e.g., cerulo-
plasmin, VEGF-A) that are later silenced
by translational repression through a
shared regulatory element located in their
30 UTRs. This element is bound by the
repressive GAIT (gamma-IFN-activated
inhibitor of translation) complex, which
interferes with interactions between two
eukaryotic initiation factors (eIFs), eIF4G
and eIF3, that collaborate to recruit small
ribosomal subunits, dramatically downre-
gulating translation (Mukhopadhyay et al.,
2009). Assembly of active GAIT complex
comprising glutamyl-prolyl tRNA synthe-
tase (EPRS), NS1-associated protein 1
(NSAP1), ribosomal protein L13a, and
glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) requires kinases whose
expression is also subject to GAIT-medi-
ated repression, providing negative
feedback that may facilitate cells return-
ing to a basal state.
In further probing GAIT-mediated re-
pression, Yao et al. unexpectedly noted
a near-constant low level of VEGF-A
protein that was independent of the
mRNA levels induced by different IFN-g
concentrations. To understand the mo-
lecular basis of this translational trickle,
mathematical modeling was undertaken
using the known regulatory components.
Fitting the model to experimental obser-
vations exposed a requirement for an
additional regulatory event, in which a
factor bound to the GAIT element should
impede access of the GAIT complex to a
small proportion of VEGF-A mRNAs, pre-
venting their repression. This conclusion
led to the search for, and the discovery
of, such a factor, EPRSN1. This C-termi-Cell 1nally truncated form of EPRS binds to
GAIT elements but fails to interact with
other GAIT-complex components due to
the absence of the C terminus. EPRSN1
is expressed at constant low levels, and
importantly, exogenous EPRSN1 was
shown to antagonize GAIT-mediated re-
pression of reporter and endogenous
mRNAs. Hence, whereas the majority of
VEGF-A, or other GAIT-element-contain-
ing mRNAs, will be bound and repressed
by the GAIT complex, a minority will
instead be bound by EPRSN1, allowing
their translation (Figure 1).
Interestingly, EPRSN1 is produced by
an unexpected alternative polyadenyla-
tion event in which cleavage at a UAU
tyrosine codon (Tyr864) within the EPRS
open reading frame, followed by adenyla-
tion, converts it to a UAA stop codon. This
process generates an mRNA without a 30
UTR and was named polyadenylation-
mediated Tyr-to-stop codon conversion
(PAY*). A small number of additional
potential PAY*-derived mRNAs were
identified but exhibited no obvious
functional or ontological relationships.
Critically, a morpholino that targets the
PAY* site within EPRSN1 pre-mRNA
decreases endogenous EPRSN1 and
VEGF-A protein expression, showing
the importance of this processing event,
and of EPRSN1, in precisely regulating
VEGF-A protein levels during GAIT-medi-
ated repression.
Although this work shows antagonism
of GAIT-mediated regulation, further
work is required to delineate the role of
this translational trickle in normal mono-
cyte and macrophage function and its49, March 30, 2012 ª2012 Elsevier Inc. 13
Figure 1. Phases of Response to IFN-g Stimulation
Restingmacrophages (unstimulated) transcribe low levels ofGAIT-element-containingmRNAs (e.g., VEGF-A), which are translated (ON).Macrophage stimulation by
IFN-g (early) upregulates transcription of GAIT-element-containing mRNAs (red line), resulting in increased protein expression (solid blue line). Inactive pre-GAIT
complexes are formed between phosphorylated EPRS, which exits the tRNA multisynthetase complex (MSC), and NSAP1. After approximately 16–24 hr IFN-g
treatment (late), GAIT-element-containingmRNAs remain abundant, but their translation is repressed (OFF) due to the formation and binding of activeGAIT complex,
comprising EPRS, NSAP1, GAPDH, and L13a. This step requires the phosphorylation-dependent release of L13a from ribosomes. GAIT-complex-associated L13a
blocks small ribosomal subunit recruitment by inhibiting the interaction of the eIF4G subunit of the eIF4F complex with eIF3 (not shown). In an apparently constitutive
process, a small amount of EPRSmRNA undergoes PAY* processing where cleavage and polyadenylation at a Tyr codon (UAU) leads to production of a truncated
version of EPRS, termed EPRSN1. EPRSN1 does not interact with GAIT-complex components but binds GAIT elements (depicted as stem loops), protecting a small
proportion of GAIT-element-containing mRNAs (ON) from GAIT-complex binding. This ensures that a low level of protein (e.g., VEGF-A) is synthesized when active
GAIT complex is repressing translation. The effect of constant ‘‘translational trickle’’ fromGAIT-element-containing mRNAs is illustrated graphically: dotted blue line
shows the levelof translatedprotein (e.g.,VEGF-A) in theabsence (EPRSN1) andsolidblue in thepresence (+EPRSN1) ofEPRSN1.Actual stoichiometry isnot implied.
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contribution to inflammatory resolution.
Moreover, as EPRSN1 mRNA is predicted
to be primate specific, it remains to be
determined whether species that lack
EPRSN1 similarly regulate GAIT-element-
containing mRNAs, imposing transla-
tional trickle by an alternative mechanism.
Conservation of the trickle in experimen-
tally tractable organisms would facilitate
probing of its physiological importance
and identification of the GAIT-regulated
mRNAs in myeloid cells whose antago-
nized repression confers a selective
advantage. Intriguingly, although GAIT-
mediated regulation has only been re-
ported in myeloid cells, nonmyeloid cell
lines also contain detectable EPRSN1
mRNA, raising questions pertaining to its
potential function in these cells.
Studies of other mRNA-specific trans-
lational repressors have shown that the
extent of regulation is determined by
various factors, including levels of active
repressor, its RNA-binding affinity,
number and position of binding sites,
and the mechanism of repression (Hentze
et al., 2007; Sonenberg and Hinnebusch,
2009). Indeed, in many cases, absolute
repressionmay not be required for normal
cellular function. Where tight repression is
imperative, repressive factors can target
multiple sequential steps during transla-
tion, so-called ‘‘failsafe’’ mechanisms, to
ensure efficient repression (Hentze et al.,
2007). In contrast, EPRSN1 has evolved,
perhaps counterintuitively, to protect a
small proportion of GAIT-element-con-
taining transcripts from repression and
thereby ensures constant low-level ex-
pression, adding a new layer of com-
plexity to the mechanisms utilized to
regulate mRNA translation. Similarly,
antagonism by a dominant-negative
form of an RNA-binding protein that
competes for a cis-element provides an
unexpected twist in translational regu-
lation, although distinct RNA-bindingproteins that compete for overlapping
binding sites have been reported (e.g.,
Lyabin et al., 2011). This type of antago-
nistic mechanism is, however, reminis-
cent of transcriptional control, where
short forms of transcription factors lack-
ing regulatory domains compete for pro-
moters (e.g., Laitem et al., 2009). Further
studies are required to determine whether
this basic principle is more widely applied
in translational control.
Alternative polyadenylation occurs in
roughly 50% of human mRNAs, predomi-
nantly within the 30 UTR, to alter posttran-
scriptional regulation (Di Giammartino
et al., 2011), although use of alternative
polyadenylation sites within introns can
produce different protein products. PAY*
represents a new mechanism to generate
proteome diversity, in which internal stop
codons (UAA) are created by cleavage
and polyadenylation at Tyr codons
(UAC or UAU), preventing such mRNAs,
which encode truncated proteins, from
being recognized and destroyed as aber-
rant by the ‘‘nonstop’’ surveillance path-
way (Frischmeyer et al., 2002). Although
the detailed mechanism underlying
EPRSN1 PAY* is unclear at this point, it
does utilize at least one canonical
cleavage and polyadenylation factor
along with the upstream (A[A/U]UAAA)
and downstream (U- or GU-rich) elements
required for standard polyadenylation,
suggesting potential for conservation of
PAY* in other species. However, their
suboptimal configuration and absence of
one or both of these cis-acting elements
in other putative human PAY* mRNAs
suggests that additional sequences and
factors are likely to be required to drive
PAY*, even inefficiently. Precedence for
this comes from factors (e.g., RNA-
binding proteins, sequence elements,
transcription efficiency) that can con-
tribute to, or regulate, 30 alternative polya-
denylation (Di Giammartino et al., 2011).Cell 1Thus it will be intriguing to examine the
PAY* mechanism in greater detail and to
determine whether it is a rare event, as
suggested by the small number of candi-
date PAY*-processed mRNAs identified,
or a more frequent event that is subject
to negative regulation.
It is now widely appreciated that trans-
lational control and mRNA processing
orchestrate regulatory gene expression
networks in a wide variety of biological
systems. Interestingly, studies of GAIT-
mediated regulation have revealed new
and unexpected complexities at multiple
levels of posttranscriptional control, pro-
viding an elaborate example of how these
events collaborate to ensure precisely
regulated gene expression.REFERENCES
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